ECSP056018A - Triazoles sustituidos con biarilo como bloqueantes del canal de sodio - Google Patents

Triazoles sustituidos con biarilo como bloqueantes del canal de sodio

Info

Publication number
ECSP056018A
ECSP056018A EC2005006018A ECSP056018A ECSP056018A EC SP056018 A ECSP056018 A EC SP056018A EC 2005006018 A EC2005006018 A EC 2005006018A EC SP056018 A ECSP056018 A EC SP056018A EC SP056018 A ECSP056018 A EC SP056018A
Authority
EC
Ecuador
Prior art keywords
compounds
pain
alone
effective amount
combination
Prior art date
Application number
EC2005006018A
Other languages
English (en)
Inventor
Prasun K Chakravarty
Michael H Fisher
Brenda Palucki
Min K Park
William H Parsons
Bishan Zhou
James P Carey
Douglas E Frantz
Michael H Kress
Damian Weaver
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP056018A publication Critical patent/ECSP056018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de triazol sustituidos con biarilo representados por la fórmula I, II o III o sales farmacéuticamente aceptables de los mismos, y un proceso para preparar dichos compuestos y sales de los mismos. Las composiciones farmacéuticas comprenden una cantidad eficaz de los presentes compuestos, solos o en combinación con uno o más compuestos terapéuticamente activos y un vehículo farmacéuticamente aceptable. Los procedimientos de tratamiento de afecciones asociadas a o causadas por la actividad de canal de sodio, incluyendo por ejemplo, dolor agudo, dolor crónico, dolor visceral, dolor inflamatorio, dolor neuropático, epilepsia, síndrome del intestino irritable, depresión, ansiedad, esclerosis múltiple y trastorno bipolar, comprenden administrar una cantidad eficaz de los presentes compuestos, solos o en combinación con uno o más compuestos terapéuticamente activos. Un procedimiento de administración de anestesia local comprende administrar una cantidad eficaz de un compuesto de la presente invención, solo o en combinación con uno o más compuestos terapéuticamente activos, y un vehículo farmacéuticamente activo.
EC2005006018A 2003-03-18 2005-09-14 Triazoles sustituidos con biarilo como bloqueantes del canal de sodio ECSP056018A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
ECSP056018A true ECSP056018A (es) 2006-01-27

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006018A ECSP056018A (es) 2003-03-18 2005-09-14 Triazoles sustituidos con biarilo como bloqueantes del canal de sodio

Country Status (34)

Country Link
US (2) US7326726B2 (es)
EP (1) EP1606269B1 (es)
JP (1) JP4482554B2 (es)
KR (1) KR100737721B1 (es)
CN (2) CN1788002A (es)
AR (1) AR044503A1 (es)
AT (1) ATE412639T1 (es)
AU (1) AU2004221885C1 (es)
BR (1) BRPI0408407A (es)
CA (1) CA2519252C (es)
CL (1) CL2004000551A1 (es)
CY (1) CY1108720T1 (es)
DE (1) DE602004017438D1 (es)
DK (1) DK1606269T3 (es)
EC (1) ECSP056018A (es)
EG (1) EG25994A (es)
ES (1) ES2314387T3 (es)
HR (1) HRP20050816A2 (es)
IS (1) IS8001A (es)
JO (1) JO2480B1 (es)
MA (1) MA27665A1 (es)
MX (1) MXPA05009847A (es)
MY (1) MY142651A (es)
NO (1) NO20054775L (es)
NZ (1) NZ542205A (es)
PE (1) PE20041066A1 (es)
PL (1) PL1606269T3 (es)
PT (1) PT1606269E (es)
RU (1) RU2356897C2 (es)
SI (1) SI1606269T1 (es)
TW (1) TWI337605B (es)
UA (1) UA81660C2 (es)
WO (2) WO2004083189A1 (es)
ZA (1) ZA200506906B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals
EP1768968A1 (en) 2004-05-20 2007-04-04 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US7855218B2 (en) 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
PL2118077T3 (pl) * 2007-02-08 2015-05-29 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
CA2847293C (en) 2011-09-16 2017-03-28 Richard Frederic Labaudiniere Solid forms of a transthyretin dissociation inhibitor
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
EP3237379B1 (en) 2014-12-23 2022-04-06 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
SG11202002706XA (en) 2017-10-05 2020-04-29 Biogen Inc Process for preparing alpha-carboxamide pyrolidine derivatives
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
WO2019171234A1 (en) * 2018-03-09 2019-09-12 Pi Industries Ltd. Heterocyclic compounds as fungicides
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (es) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
AR023171A1 (es) 1999-03-26 2002-09-04 Cocensys Inc Pirazoles, imidazoles, oxazoles, tiazoles, y pirroles sustituidos por arilo, y el uso de los mismos.
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
AU2003248861B2 (en) * 2002-07-09 2009-01-22 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals

Also Published As

Publication number Publication date
AR044503A1 (es) 2005-09-14
BRPI0408407A (pt) 2006-03-21
US20080171777A1 (en) 2008-07-17
CN1788002A (zh) 2006-06-14
RU2356897C2 (ru) 2009-05-27
KR20050109583A (ko) 2005-11-21
MY142651A (en) 2010-12-15
HRP20050816A2 (hr) 2006-04-30
DE602004017438D1 (de) 2008-12-11
PT1606269E (pt) 2008-12-16
ATE412639T1 (de) 2008-11-15
PE20041066A1 (es) 2005-01-22
NZ542205A (en) 2008-11-28
CA2519252A1 (en) 2004-09-30
AU2004221885A1 (en) 2004-09-30
RU2005132168A (ru) 2006-04-27
DK1606269T3 (da) 2009-02-09
CY1108720T1 (el) 2013-09-04
IS8001A (is) 2005-08-29
JP4482554B2 (ja) 2010-06-16
EP1606269A1 (en) 2005-12-21
US7326726B2 (en) 2008-02-05
UA81660C2 (ru) 2008-01-25
NO20054775D0 (no) 2005-10-17
US20050119261A1 (en) 2005-06-02
CL2004000551A1 (es) 2005-01-21
US7572822B2 (en) 2009-08-11
CN101289428A (zh) 2008-10-22
EP1606269B1 (en) 2008-10-29
WO2004083190A1 (en) 2004-09-30
AU2004221885B2 (en) 2010-04-22
TWI337605B (en) 2011-02-21
CA2519252C (en) 2008-11-18
ZA200506906B (en) 2007-02-28
PL1606269T3 (pl) 2009-04-30
MXPA05009847A (es) 2005-12-05
SI1606269T1 (sl) 2009-02-28
WO2004083189A1 (en) 2004-09-30
KR100737721B1 (ko) 2007-07-11
ES2314387T3 (es) 2009-03-16
NO20054775L (no) 2005-12-16
JO2480B1 (en) 2009-01-20
JP2006520782A (ja) 2006-09-14
AU2004221885C1 (en) 2010-09-23
MA27665A1 (fr) 2005-12-01
EG25994A (en) 2012-11-28
TW200505876A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
ECSP056018A (es) Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
NO20062676L (no) Substituerte triazoler som natriumkanalblokkere
ES2151599T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido como inhibidores de matriz metaloproteinasas.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
AR084473A1 (es) Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
RU2013119129A (ru) Органические соединения
RU2009114159A (ru) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
CO6270360A2 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
WO2008157404A3 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MX2022012056A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento.
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
RU2008129623A (ru) Ингибиторы ccr9 активности
DOP2004000850A (es) Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
RU2013113301A (ru) Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
MX2022011240A (es) Azálidos de urea inmunomoduladores.
JPWO2020079165A5 (es)
MX2021013347A (es) Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.
RU2011147382A (ru) Соединения, создающие физиологический эффект
WO2023172475A3 (en) Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors
WO2023177563A3 (en) Fused pyrazole amide analogs as glucosylceramide synthase inhibitors
SE0201881D0 (sv) Novel compounds, their use, and preparation